Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder

被引:17
作者
Ginsberg, Lawrence D. [1 ]
机构
[1] Red Oak Psychiat Associates PA, Houston, TX 77090 USA
关键词
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; DESVENLAFAXINE; 50; 100; MG/DAY; EFFICACY; SAFETY; ESCITALOPRAM; MIRTAZAPINE; OUTPATIENTS; PREVENTION;
D O I
10.1017/S1092852900026353
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Despite significant progress in the,development of antidepressant therapies, tolerability remains an important factor associated with the selection of appropriate antidepressant treatment. Side effects commonly reported by depressed patients taking antidepressants include weight gain, sexual dysfunction, and gastrointestinal effects. Tolerability issues associated with antidepressants can negatively impact treatment outcomes for patients with major depressive disorder. In addition, a drug's tolerability profile substantially influences a physician's choice of specific antidepressant therapy. Despite the availability of many antidepressants, empirical clinical evidence to guide physicians in making the best choice is limited and not always clear. Thus, it is key for clinicians to understand the short-and long-term outcomes and side effect profiles of the available antidepressants. CNS Spectr. 2009;14:12(Suppl 12):8-14.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 36 条
[1]
[Anonymous], 2000, Am J Psychiatry, V157, P1
[2]
[Anonymous], 2008, PRIST PACK INS
[3]
Mirtazapine orally disintegrating tablet versus sertraline:: A prospective onset of action study [J].
Behnke, K ;
Sogaard, J ;
Martin, S ;
Bäuml, J ;
Ravindran, AV ;
Ågren, H ;
Vester-Blokland, ED .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :358-364
[4]
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial [J].
Boyer, Patrice ;
Montgomery, Stuart ;
Lepola, Ulla ;
Germain, Jean-Michel ;
Brisard, Claudine ;
Ganguly, Rita ;
Padmanabhan, Sudharshan K. ;
Tourian, Karen A. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (05) :243-253
[5]
Prevalence of sexual dysfunction among newer antidepressants [J].
Clayton, AH ;
Pradko, JF ;
Croft, HA ;
Montano, CB ;
Leadbetter, RA ;
Bolden-Watson, C ;
Bass, KI ;
Donahue, RMJ ;
Jamerson, BD ;
Metz, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :357-366
[6]
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder [J].
Clayton, Anita ;
Kornstein, Susan ;
Prakash, Apurva ;
Mallinckrodt, Craig ;
Wohlreich, Madelaine .
JOURNAL OF SEXUAL MEDICINE, 2007, 4 (04) :917-929
[7]
*E LILL CO, 2007, CYMB PACK INS
[8]
Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment [J].
Fava, M ;
Judge, R ;
Hoog, SL ;
Nilsson, ME ;
Koke, SC .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) :863-867
[9]
Ferguson JM, 2001, J CLIN PSYCHIAT, V62, P22
[10]
Comparative Risk for Harms of Second-Generation Antidepressants A Systematic Review and Meta-Analysis [J].
Gartlehner, Gerald ;
Thieda, Patricia ;
Hansen, Richard A. ;
Gaynes, Bradley N. ;
DeVeaugh-Geiss, Angela ;
Krebs, Erin E. ;
Lohr, Kathleen N. .
DRUG SAFETY, 2008, 31 (10) :851-865